Physician profile
Amber Vitale
NPI 1083149785
$2,593.73
in general payments reported to CMS, 2019-2025
16 companies · $17.49 in 2025
The $17.49 reported for 2025 was less than what a typical Family Health provider received nationally (typical 2025 total: $209).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $355 · 2022: $1,455 · 2023: $640 · 2024: $127 · 2025: $17.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $685 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $684.80 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $728.18 | 2021-2023 | Enhertu |
| Janssen Pharmaceuticals, INC | $401.04 | 2021-2024 | Xarelto |
| Janssen Biotech, INC. | $353.69 | 2022-2023 | Darzalex, Tecvayli |
| Incyte Corporation | $207.98 | 2022-2023 | Monjuvi |
| Merck Sharp & Dohme LLC | $161.79 | 2022-2025 | Lynparza, Keytruda |
| Janssen Scientific Affairs, LLC | $124.94 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $123.46 | 2023 | Reblozyl |
| Blueprint Medicines Corporation | $113.96 | 2022 | |
| Dendreon Pharmaceuticals LLC | $90.35 | 2021 | |
| Abbvie INC. | $76.49 | 2023-2024 | |
| Acrotech Biopharma INC. | $54.89 | 2024 | Beleodaq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.75 | 2022-2023 | Jardiance |
| Genmab U.S., INC. | $34.39 | 2023 | Tivdak |
| Glaxosmithkline, LLC. | $28.39 | 2023 | Zejula, Jemperli |
| Lundbeck LLC | $20.57 | 2024 | Abilify Asimtufii |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $19.86 | 2023 | Myosure Tissue Removal Device |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Vitale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.